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Abstract
Bilateral visual loss secondary to inherited
optic neuropathies is an important cause of
registrable blindness among children and
young adults. The two prototypal disorders
seen in clinical practice are Leber hereditary
optic neuropathy (LHON) and autosomal
dominant optic atrophy (DOA). About 90%
of LHON cases are due to one of three
mitochondrial DNA (mtDNA) point muta-
tions: m.3460G4A, m.11778G4A, and
m.14484T4C, which affect critical complex I
subunits of the mitochondrial respiratory
chain. The majority of patients with DOA
harbour pathogenic mutations within
OPA1, a nuclear gene that codes for a multi-
functional inner mitochondrial membrane
protein. Despite their contrasting genetic
basis, LHON and DOA share overlapping
pathological and clinical features that serve to
highlight the striking tissue-specific vul-
nerability of the retinal ganglion cell (RGC)
layer to disturbed mitochondrial function. In
addition to severe visual loss secondary to
progressive optic nerve degeneration,
a subgroup of patients will also develop a
more aggressive syndromic phenotype
marked by significant neurological deficits.
The management of LHON and DOA remains
largely supportive, but major advances in our
understanding of the mechanisms underpin-
ning RGC loss in these two disorders are
paving the way for novel forms of treatment
aimed at halting or reversing visual
deterioration at different stages of the disease
process. In addition to neuroprotective
strategies for rescuing RGCs from irreversible
cell death, innovative in vitro fertilisation
techniques are providing the tantalising pro-
spect of preventing the germline transmission
of pathogenic mtDNA mutations, eradicating
in so doing the risk of disease in future
generations.
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Introduction
Hereditary optic nerve disorders result in
significant chronic visual morbidity, and the
minimum prevalence of affected individuals in
the population has been estimated at 1 in 10 000.1
Leber hereditary optic neuropathy (LHON) and
autosomal dominant optic atrophy (DOA) are
the two classical paradigms for this group of
disorders, and they account for most of the
inherited optic atrophy cases seen in clinical
practice. LHON is caused by mitochondrial
DNA (mtDNA) point mutations, whereas, in
DOA, the majority of cases are due to pathogenic
mutations in the OPA1 gene, which codes for an
inner mitochondrial membrane protein.1,2
Strikingly, both LHON and DOA share the same
characteristic pathological features with selective
degeneration of the retinal ganglion cell (RGC)
layer, leading to progressive optic nerve
degeneration and the onset of visual symptoms.3
Rarer autosomal recessive optic atrophy genes
have also been identified and a common theme is
emerging, with all of them so far encoding for
key components of the mitochondrial
machinery.1,2 RGCs are therefore exquisitely
sensitive to mitochondrial dysfunction, and the
elucidation of the mechanisms involved is
opening the way for therapeutic interventions
targeting different stages of the disease process.
In this review, recent advances in our
understanding of LHON and DOA will be
discussed, in addition to the practical
management of this group of patients and
emerging treatment options.
Mitochondrial disorders
Oxidative phosphorylation
Mitochondria are ubiquitous intracellular
organelles present in all nucleated eukaryotic
cells.4,5 They form a highly interconnected
network extending throughout the cell’s
structure and their overall morphology is
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dictated by the balance between mitochondrial fusion
and fission. Mitochondria are bounded by two
membranes and this arrangement creates two distinct
anatomical compartments, namely, the intermembrane
space and the internal matrix space. The mitochondrial
respiratory chain consists of five multi-subunit
complexes (I-V) embedded within the inner
mitochondrial membrane, and it accounts for the bulk of
the cell’s adenosine triphosphate (ATP) production
through the process of oxidative phosphorylation
(OXPHOS).4,5 In order to increase the effective surface
area available for mitochondrial biogenesis, the inner
mitochondrial membrane is thrown into multiple
infoldings, known as cristae, and, unsurprisingly,
aberrant cristae morphology is a frequent ultrastructural
feature of disorders caused by mitochondrial
dysfunction. OXPHOS is a tightly regulated process that
involves the donation of high-energy electrons to
complex I by the intermediate products (NADH and
FADH2) generated from the beta-oxidation of fatty acids
and glycolysis. As these electrons shuttle along the
mitochondrial respiratory chain, a significant amount of
energy is released and this is used to actively pump
protons from the matrix compartment into the
intermembrane space. Ubiquinone is a fat-soluble
molecule present at a very high concentration within the
inner mitochondrial membrane, and it has a unique role in
OXPHOS as the only carrier that can efficiently transfer
electrons from complexes I and II to complex III. The
electrochemical proton gradient generated across the inner
mitochondrial membrane is eventually harnessed by
complex V (ATP synthase) for the conversion of ATP from
adenosine diphosphate (ADP) and inorganic phosphate.
Mitochondrial genetics
Mitochondria are unique in possessing their own genetic
material in the form of a double-stranded circular
DNA molecule about 16 569 base-pair long.4,5 The
mitochondrial genome is therefore very compact, but it
codes for structural and functional components that are
indispensable for normal mitochondrial function,
including two ribosomal RNAs (12S and 16S rRNA), 22
transfer RNAs (tRNAs), and 13 polypeptide subunits of
the mitochondrial respiratory chain complexes (I, III, V,
and V). Another remarkable feature of mitochondrial
genetics is its very high copy number with several
thousands of mtDNA molecules being present in
metabolically active cells such as neurons. Unlike nuclear
DNA, mtDNA replicates continuously in dividing as
well as in non-dividing cells, and this process occurs
independently of the cell cycle. As a result of this relaxed
replication machinery, a cell’s total mtDNA content can
be adjusted according to its bioenergetic requirements
under both physiological and pathological conditions.
Furthermore, the large number of mtDNA molecules
present in each cell creates two possible genetic
situations, referred to as homoplasmy or heteroplasmy.
In the heteroplasmic state, two or more mtDNA variants
are present at a specific nucleotide position, and this
genetic admixture has been implicated in the variable
disease expression that typifies mitochondrial disorders.6
Most pathogenic mtDNA mutations are heteroplasmic,
and mitochondrial respiratory chain activity becomes
compromised when the level of the mutant species
exceeds a critical threshold (60–80%), which is both
mutation and tissue specific.4,5 In terms of genetic
counselling, the mitochondrial genome shows strict
maternal inheritance and male mutation carriers can be
reassured that transmission to their own offspring will not
occur. In contrast, all the children of a homoplasmic female
carrier will harbour their mother’s mtDNA mutation.
The situation is rather more complex for a heteroplasmic
mother as she could transmit a higher or a lower level
of her mtDNA mutation to a particular offspring, which
could influence the latter’s risk of becoming clinically
affected. The sometimes rapid shifts in mitochondrial allele
frequencies that occur between maternally related
generations have been explained by a ‘mitochondrial
bottleneck’ operating in the female germline.7
Nuclear–mitochondrial interactions
Mitochondria have limited autonomy and they rely
heavily on the nuclear genome for the vast majority of
proteins required for mtDNA replication, transcription,
and translation.4,5 In 1988, two seminal papers were
published linking for the first time specific mtDNA
mutations with human disease: large-scale single
mtDNA deletions in patients with mitochondrial
myopathies and the m.11778G4A point mutation in
families with LHON.8,9 Families segregating classical
mitochondrial phenotypes in a clear-cut Mendelian
pattern of inheritance were subsequently reported, and
the existence of nuclear genetic defects disrupting
mitochondrial proteins was widely suspected. This
hypothesis was confirmed in 2001, when mutations in the
nuclear genes, POLG and PEO1, were identified in
families with autosomal dominant chronic progressive
external ophthalmoplegia (CPEO).10 The pathological
hallmark of all these nuclear mitochondrial disorders is
mtDNA instability, which can be quantitative in nature
with a reduction in mtDNA copy number (depletion) or
qualitative with the accumulation of high levels of somatic
mtDNA mutations (predominantly deletions) in affected
tissues. MtDNA molecules are located within the matrix
compartment where they are packaged within intricate
physical structures known as nucleoids.11 Although the
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components of these fundamental replicative units have
not yet been fully established, both POLG and PEO1
are closely associated with mammalian nucleoids,
highlighting the critical role played by these two proteins
in mitochondrial genome maintenance. Mitochondrial
transcription factor A (TFAM) has also been identified as a
major nucleoid-organising protein responsible for
packaging mtDNA and activating mitochondrial
transcription.10 From a diagnostic perspective, the
disruption of OXPHOS that ensues from the accumulation
of secondary mtDNA abnormalities can be easily detected
in skeletal muscle biopsies as cytochrome c oxidase
(COX)-negative fibres.6 When present, these various
molecular and histochemical features can be extremely
helpful in the investigation of patients with suspected
mitochondrial disease as they provide strong clues
pointing towards an underlying nuclear genetic defect.
Leber hereditary optic neuropathy
Molecular genetics
LHON (OMIM 535000) is the most common of the
primary mitochondrial DNA (mtDNA) disorders, and
the minimum prevalence has been estimated at 1 in
31 000 in the North of the United Kingdom (Figure 1).12
Comparable prevalence figures of 1 in 39 000 and 1 in
50 000 have been reported in epidemiological studies from
the Netherlands and Finland, respectively.13,14 The
majority of cases (90%) are due to one of three mtDNA
point mutations: m.3460G4A (MTND1), m.11778G4A
(MTND4), and m.14484T4C (MTND6), which affect key
complex I subunits of the mitochondrial respiratory chain.
The m.11778G4A mutation is by far the most common
pathogenic mutation accounting for B70% of all LHON
cases worldwide.1,2 The one notable exception to this rule
is the preponderance of the m.14484T4C mutation (B
90%) in patients of French Canadian descent secondary to
a mutational founder event.15 In most diagnostic
laboratories, screening for the three ‘primary’ LHON
mutations is carried out in the first instance in suspected
cases. If this is negative and there is still a strong clinical
suspicion of LHON, full mitochondrial genome
sequencing can be considered. However, close liaison with
an experienced laboratory is essential, not only because it
remains a time consuming and expensive exercise, but
interpretation of the sequencing results is not always
straightforward.16 A number of relatively rare pathogenic
mtDNA variants causing LHON have been confirmed, but
others have only been reported in single patients or
families and additional irrefutable proof of pathogenicity
is still needed, which greatly complicates patient
counselling (Table 1).
Figure 1 The prevalence of inherited optic neuropathies in the North of the United Kingdom. *Includes patients with LHON and DOA.16
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Clinical features
Fundal abnormalities such as peripapillary telangiectatic
vessels and transient retinal nerve fibre layer (RNFL)
oedema can be observed in some asymptomatic LHON
carriers.17,18 On more detailed psychophysical testing,
some unaffected LHON carriers also show subclinical
optic nerve impairment with reduced colour vision and
contrast sensitivity, and subnormal responses on
multifocal electroretinography and visual evoked
potentials.19 Disease conversion in LHON is
characterised by acute or subacute, painless, central
visual loss in one eye, followed weeks to months later by
the fellow eye.20 The median inter-eye delay is 6–8
weeks, and the second eye is invariably affected within 1
year of disease onset. Bilateral simultaneous onset occurs
in a proportion of patients (B25%) with the caveat that
some individuals are probably unaware that visual loss
had been ongoing unnoticed in one eye before the second
eye being involved. Although there are rare case reports
of unilateral optic nerve involvement in LHON, it is
important to exclude other underlying pathological
causes in these highly atypical presentations. The peak
age of onset is in the second and third decades of life, and
it is unusual for LHON carriers to experience visual loss
beyond the age of 50 years.20 Visual acuity worse than
6/60 is the norm at the nadir, and there is an associated
dense central or centrocecal scotoma with profound
dyschromatopsia. Interestingly, the pupillary light
reflexes are relatively preserved in LHON due to the
sparing of a special class of melanopsin-containing
RGCs that seem more resistant to mitochondrial
dysfunction.21
A careful dilated fundus examination can be
particularly informative in the acute stage of LHON as
patients classically exhibit a number of distinct
abnormalities, namely, optic disc hyperaemia,
peripapillary telangiectatic vessels, vascular tortuosity,
and swelling of the retinal nerve fibre layer (RNFL)
secondary to axoplasmic stasis (Figure 2a).1,2 It is
important to stress that the posterior pole can look
entirely normal in a proportion (20–40%) of affected
LHON carriers and the diagnosis may be delayed until
optic disc pallor becomes apparent at around 6 weeks.
This group of patients are frequently labelled as having
functional visual loss, at least initially. In addition to
pallor of the neuroretinal rim, non-glaucomatous
cupping of the optic disc is also a recognised pathological
feature of longstanding LHON cases, reflecting the
progressive loss of RGCs that occurs in the chronic phase
of the disease process.1,2
The visual prognosis in LHON is poor and the
majority of patients will remain legally blind with a
significant detrimental impact on their overall quality of
life.22 Spontaneous visual improvement can occur and it
is most likely within the first year. Remarkably, it has also
been reported several years or even decades following
the initial visual loss. Visual recovery is usually
heralded by the appearance of small islands
of vision in the central visual field and, as the scotoma
Table 1 Mitochondrial DNA variants identified in patients with Leber hereditary optic neuropathy
Mitochondrial
gene
Nucleotide change
Common variants
(B 90%)
MTND1 m.3460G4Aa
MTND4 m.11778G4Aa
MTND6 m.14484T4Ca
Rare variants
(B 10%)
MTND1 m.3376G4A, m.3635G4Aa, m.3697G4A, m.3700G4Aa, m.3733G4Aa, m.4025C4T,
m.4160T4C, m.4171C4Aa
MTND2 m.4640C4A, m.5244G4A
MTND3 m.10237T4C
MTND4 m.11696G4A, m.11253T4C
MTND4L m.10663T4Ca
MTND5 m.12811T4C, m.12848C4T, m.13637A4G, m.13730G4A
MTND6 m.14325T4C, m.14568C4T, m.14459G4Aa, m.14729G4A, m.14482C4Aa, m.14482C4Ga,
m.14495A4Ga, m.14498C4T, m.14568C4Ta, m.14596A4T
MTATP6 m.9101T4C
MTCO3 m.9804G4A
MTCYB m.14831G4A
a These mtDNA variants are definitely pathogenic. They have been identified in Z2 independent LHON pedigrees and show segregation with affected
disease status.
The remaining putative LHON mutations have been found in singleton cases or in a single family, and additional evidence is required before
pathogenicity can be irrefutably ascribed.1
Treatment of inherited optic neuropathies
P Yu-Wai-Man et al
524
Eye
gets concurrently less dense, these fenestrations can
greatly help with scanning vision and peripheral
navigation.1,2 LHON carriers harbouring the
m.14484T4C mutation have the best visual prognosis
with a partial visual recovery rate of 37–58%, compared
with 4–25% for the m.11778G4A mutation.12,23–25 Other
reported positive prognostic factors for visual recovery in
LHON include an earlier age of onset (o20 years),
especially among young children; a subacute
presentation with slow visual deterioration; and a
relatively large optic disc.26,27
LHON plus phenotypes
An abiding mystery of LHON is the tissue-specific
vulnerability of the RGC layer despite the ubiquitous
presence of the pathogenic mtDNA mutation. Although
visual loss is the defining feature of this mitochondrial
disorder, cardiac conduction defects and neurological
abnormalities such as ataxia, peripheral neuropathy,
myopathy, and dystonia have been reported to be more
common among LHON carriers compared with
controls.1,2 However, because of the relative rarity of
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Figure 2 (a) Fundal abnormalities in Leber hereditary optic neuropathy. This m.11778G4A male carrier experienced visual loss in his
right eye initially, followed 8 months later by his left eye. The fundus pictures were taken 1 month after the left eye had become
affected. Best-corrected visual acuities at that point were counting fingers in the right eye and 6/36 in the left eye. There is temporal
pallor of the right optic disc, whereas the left optic disc is still hyperaemic consistent with the more recent disease onset. Vascular
tortuosity of the central retinal vessels can also be observed in both eyes. L, left eye; R, right eye; T, temporal papillomacular bundle.
(b) Pattern of retinal ganglion cell loss in autosomal dominant optic atrophy. The patient harbours a pathogenic OPA1 nonsense
mutation within exon 27 (c.2713C4T, p.R905X). Pallor of the optic nerve head is more pronounced temporally and optical coherence
tomography (OCT) imaging shows relative sparing of the nasal peripapillary retinal nerve fibre layer (RNFL). OCT measurements
were obtained with the spectral-domain Cirrus platform (Carl Zeiss Meditec, Dublin, CA, USA). In addition to the average thickness,
RNFL values are shown for each individual quadrant and each clock hour. The analysis software automatically selects the appropriate
age-corrected normative range for the patient, and the RNFL measurements (dark traces) are represented within colour-coded
distribution centiles: (i) redo1%, (ii) yellow 1–5%, and (iii) green 5–95%.
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these events, the causal link between the underlying
mtDNA mutation and the development of these
extraocular manifestations remains largely
circumstantial. In 1992, Anita Harding and colleagues
described a rather intriguing association between the
m.11778G4A LHON mutation and a demyelinating
syndrome that was clinically and radiologically
indistinguishable from multiple sclerosis (MS).28
Harding disease, as this association became known
subsequently, is more common among female LHON
carriers and those harbouring the m.11778G4A
mutation. However, additional functional work is
needed to determine whether the mtDNA mutation is
directly influencing the development of an MS-like
illness in addition to visual failure, or whether this
association simply represents a statistical chance
occurrence.29,30 In a small number of families from
Holland, Australia, and North America, rare pathogenic
mtDNA variants have been linked with particularly
severe LHON plus phenotypes complicated by spastic
dystonia, ataxia, juvenile-onset encephalopathy, and
psychiatric disturbances.1
Incomplete penetrance and sex bias
Not all LHON mutation carriers will experience visual
loss during their lifetime. The conversion rate for male
carriers is B50% compared with B10% for female
carriers.1 LHON is therefore characterised by both
marked incomplete penetrance and a striking male bias
for visual loss. The secondary factors that modulate the
phenotypic expression of the underlying pathogenic
mtDNA mutation have been the subject of intense
research over the past two decades. Although we do not
yet have the full picture of what is proving to be a
relatively complex disease, a number of genetic,
hormonal, and environmental factors have been
identified, some of which are particularly relevant to
patient counselling and the development of drug
treatments for LHON.
Heteroplasmy is thought to influence disease
penetrance based on the observation that affected LHON
carriers have mutation levels greater than 60% in
peripheral blood leukocytes.31 However, incomplete
penetrance is still observed among heteroplasmic carriers
with mutation levels exceeding this nominal threshold,
and the majority of LHON families (80–90%) harbour
homoplasmic mtDNA mutations.12 Heteroplasmy is
therefore not a major contributor to the incomplete
penetrance pattern seen in LHON. Another factor that
could be modulating the risk of visual loss in LHON is
the mitochondrial genetic background on which the
pathogenic mtDNA mutation is segregating. The
mitochondrial genome is highly polymorphic, and,
during human evolution, ancient mtDNA variants have
gradually clustered together in specific combinations
known as haplogroups.4,5 Mitochondrial haplogroups
have a differential effect on the efficiency of the
mitochondrial respiratory chain, and this could possibly
influence the overall deleterious impact of the LHON
mutation on RGC survival.32,33 In a large meta-analysis
of Caucasian LHON pedigrees, haplogroup J was
associated with a significantly increased risk of visual
loss among m.11778G4A and m.14484T4C carriers,
whereas m.3460G4A carriers were more likely to
become affected on a haplogroup K background.34
LHON carriers with the m.11778G4A mutation had a
lower risk for visual loss when the mutation arose on
haplogroup H. Other haplogroup associations have been
reported in families with LHON from mainland China,
but none in those from South-East Asia.35,36 The
influence of specific mtDNA polymorphisms on the risk
of visual failure in LHON is therefore not entirely clear-
cut, and further investigation is warranted.
The predominance of affected males in LHON cannot
be explained by mitochondrial inheritance. Segregation
analysis of a large number of LHON families was
consistent with the existence of a recessive X-linked
susceptibility gene acting in synergy with the mtDNA
mutation to precipitate visual loss.37 Three independent
linkage studies have revealed overlapping candidate
regions on the X-chromosome, but the actual modifier
gene has still not yet been identified.38–40 The existence of
autosomal nuclear modifiers in LHON remains a distinct
possibility, and the situation could prove even more
complex if different combinations of nuclear genes are
segregating in different ethnic populations.
Another obvious explanation for the striking marked
male bias in LHON is a protective benefit from female
sex hormones. Interestingly, treatment with 17b-
oestradiol resulted in reduced reactive oxygen species
(ROS) levels, increased activity of the antioxidant
enzyme superoxide dismutase (SOD), and more efficient
mitochondrial biogenesis in LHON cybrid cell lines.41 As
RGC cell bodies have a high concentration of oestrogen
b receptors, supplementation with oestrogen-like
compounds represents an attractive therapeutic option.
Various environmental triggers have been implicated in
precipitating the onset of visual loss in LHON, including
head trauma, psychological stress, exposure to industrial
toxins, and drugs with mitochondrial toxic effects such
as antiretrovirals and ethambutol.1,2 A recent multicentre
study that enrolled 125 Northern European LHON
pedigrees has provided important insight into the role of
smoking and alcohol consumption on disease
expression.42 Smoking was strongly associated with an
increased risk of visual loss, and this detrimental effect
was more marked for heavy smokers compared with
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light smokers. Various toxins present in cigarette smoke
are capable of depressing mitochondrial ATP synthesis
either through a direct inhibitory effect on complex I
activity or by reducing arterial oxygen concentration.
There was also a trend towards an increased risk of
visual failure with heavy binge drinking, but this effect
was not as marked as for smoking.
Disease mechanisms
The papillomacular bundle is affected early and much
more severely in LHON. The preferential involvement of
the RGCs within the papillomacular bundle is likely
related to their relatively small calibres and limited
mitochondrial energetic reserves.43 Two major
mechanisms have been proposed to precipitate RGC loss
in LHON—a biochemical respiratory chain defect and
increased levels of reactive oxygen species (ROS).44 There
are supporting lines of evidence for both these
pathological pathways, and they represent obvious
therapeutic targets to halt the catastrophic loss of RGCs
that occurs during the acute phase of LHON. The three
most common primary LHON mutations (m.3460G4A,
m.11778G4A, and m.14484T4C) all affect critical
complex I subunits, and impaired complex I-driven ATP
synthesis has been identified using both in vitro and
in vivo biochemical assays.1,3 A mouse model has
recently been developed that replicates some of the key
histopathological features seen in the optic nerves of
affected LHON patients, namely the preferential
degeneration of the smallest calibre RGC fibres, marked
axonal swelling, and the accumulation of dysmorphic
mitochondria within demyelinated segments.45
Increased ROS levels were observed with no reduction in
ATP synthesis, strongly supporting oxidative stress as
the major mechanism driving the loss of RGCs, at least in
that specific mouse model.
Autosomal dominant optic atrophy
Molecular genetics
Autosomal dominant optic atrophy (DOA, OMIM
605290) is the most commonly diagnosed inherited optic
neuropathy, and, in a recent epidemiological study, the
minimum prevalence was estimated at 1 in 25 000 in the
North of the United Kingdom (Figure 1).46 The majority
of families with DOA (B 60%) harbour pathogenic
mutations in OPA1 (3q28-q29), which codes for a
dynamin-related GTPase protein located within the inner
mitochondrial membrane.47,48 It is a ubiquitous protein
and abundant levels have been detected in RGCs, the
inner ear, and the brain. OPA1 is highly polymorphic and
over 200 pathogenic mutations have been identified with
hotspots in the catalytic GTPase domain (exons 8–15) and
the dynamin central domain (exons 16–23).49 Most
pathogenic mutations result in a marked reduction in the
level of the OPA1 protein, and the pathological
significance of haploinsufficiency is further highlighted
by those rare families with large-scale deletions spanning
the entire OPA1 coding region.50
Clinical features
DOA has an insidious onset in early childhood and it
typically presents with bilateral, symmetrical, central
visual loss and dyschromatopsia. There is a wide
variability in disease severity with visual acuities ranging
from 6/6 to the detection of hand movement.51
Asymptomatic OPA1 mutation carriers with subclinical
disease are frequently identified during contact tracing. If
there is no definite family history, it is therefore
important to examine other family members of a patient
with suspected inherited optic atrophy to establish more
clearly the pattern of inheritance. Visual deterioration has
been reported in 19 to 67% of patients with DOA on long-
term follow-up, with 13 to 46% being registered legally
blind.1,2 Visual decline in DOA is usually slow, and a
good proportion of patients will retain good functional
vision late into their disease. However, the rate of visual
loss can be highly variable both between and within
families, and some patients with DOA experience a much
faster rate of disease progression.51
Similar to LHON, the pathological hallmark of DOA is
the preferential early loss of RGCs within the
papillomacular bundle, accounting for the distinctive
temporal wedge of pallor that is commonly observed at the
optic nerve head (Figure 2b). However, pallor of the
neuroretinal rim can be subtle, and the demonstration of
pathological thinning of the retinal nerve fibre layer
(RNFL), especially in the temporal quadrant, with optical
coherence tomography (OCT) imaging can be particularly
helpful.52 Electrophysiological testing can also be informa-
tive in these equivocal cases. The pattern visual evoked
potentials in DOA is characterised by abnormally pro-
longed latencies and a variable decrease in magnitude. The
N95 component of the pattern electroretinogram (pERG) is
usually selectively depressed consistent with primary
dysfunction of the RGC layer. Deep excavation of the optic
disc with an enlarged cup-to-disc ratio greater than 0.5 is
another typical morphological feature observed in DOA.51
It is therefore not surprising that patients with DOA are
often misdiagnosed as having normal tension glaucoma,
especially if the degree of optic disc pallor is mild and there
is no convincing family history. Limited post mortem
studies suggest the relative preservation of melanopsin-
containing RGCs, and this could account for the lack of an
afferent pupillary defect in patients with DOA, which is
another clinical feature shared with LHON.21
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DOA plus phenotypes
Progressive central visual loss is the defining feature of
DOA, but with greater access to molecular genetic
testing, a much broader array of clinical presentations
have now been linked to pathogenic OPA1 mutations.
The most common extraocular feature is sensorineural
hearing loss developing in the first two decades of life
and a specific OPA1 mutation in exon 14 (c.1334G4A,
p.R445H) has been strongly associated with the
co-occurrence of deafness and optic atrophy.53 In a large
multicentre study, nearly 20% of OPA1 mutation carriers
developed a more severe neuromuscular phenotype
complicated by varying combinations of deafness, ataxia,
myopathy, peripheral neuropathy, and CPEO.53
Interestingly, some patients have also been reported with
clinical features indistinguishable from MS, hereditary
spastic paraplegia (HSP), and the inherited
spinocerebellar degenerations. From a mechanistic
perspective, these so-called dominant optic atrophy plus
(DOAþ ) phenotypes confirm that the pathological
consequences of OPA1 mutations are not limited to
RGCs, but they clearly extend to other central neuronal
populations, peripheral nerves, and skeletal muscle.
Disease mechanisms
OPA1 is a multifunctional protein located within the inner
mitochondrial membrane. It is a critical pro-fusion
protein and pathogenic OPA1 mutations result in marked
mitochondrial network fragmentation.54 This physical
disruption has a knock-on effect on the stability of the
mitochondrial respiratory chain complexes, resulting in
increased ROS levels and a reduction in overall ATP
synthesis.55,56 Pro-apoptotic cytochrome c molecules are
carefully sequestered within the cristae spaces by the
zipper-like action of OPA1 and mitochondria are major
stores of calcium.57,58 Mitochondrial network
fragmentation results in the uncontrolled release of these
potent pro-apoptotic factors, which ultimately trigger
irreversible cell death. Although the mechanisms still
need to be fully elucidated, OPA1 mutations result in
mitochondrial genome instability and the accumulation
of multiple mtDNA deletions in affected tissues of some
patients.59 Patients with DOAþ phenotypes harbour
significantly higher levels of these somatic mtDNA
abnormalities suggestive of a contributory role in the
development of the more severe neuromuscular
complications.53 Although OPA1 regulates a whole host
of interrelated cellular pathways, compromised OXPHOS
and elevated ROS levels are two major disease
mechanisms that overlap with LHON, raising the exciting
prospect of generic neuroprotective strategies applicable
to both these mitochondrial optic neuropathies.
Patient Management
General supportive measures
The sudden onset of severe visual loss in LHON causes
significant distress and anxiety for patients and their
families. The majority of patients are young healthy
adults, and the shock of receiving a genetic confirmation
of LHON is often compounded by the diagnostic delays
and uncertainties that are not uncommon for rare genetic
disorders. Although DOA has a less marked presentation
compared with LHON, visual loss can be progressive
and in a quality of life survey, half of all the patients
interviewed reported high levels of anxiety and
depression.60 Clinicians therefore have an important role
to play in facilitating access to rehabilitative services such
as low visual aids and occupational therapy. Patient
groups and information websites can also provide
invaluable support, especially in the immediate period
after a diagnosis has been made (https://sites.google.
com/site/planetleeder/lhon and http://www.lhon.org/
lhon/LHON.html, accessed on 8 December 2013). In
addition to visual loss, patients with LHON and DOA
can also develop neurological features such as ataxia,
peripheral neuropathy, and hearing impairment.
Clinicians need to be aware of these ‘plus’ phenotypes to
ensure their early detection, and patients in this high-risk
group are best served by a multidisciplinary team to
aggressively manage and minimise the functional
consequences of these systemic complications.
Genetic counselling
The mitochondrial genome is maternally inherited and
male LHON carriers can be reassured that their children
are not at risk of inheriting their genetic defect. In
contrast, female carriers will transmit the mutation to all
their children, but, if the mutation is heteroplasmic, the
level of the mtDNA mutation transmitted can fluctuate,
sometimes markedly, as a result of the mitochondrial
genetic bottleneck. Prenatal testing for heteroplasmic
female LHON carriers is therefore unhelpful because the
mutant load detected in amniocytes and chorionic villi
may not correspond to that in other fetal cell populations,
especially those destined to mature into RGCs.
A frustrating aspect of the management of LHON is the
current inability to accurately predict whether a familial
carrier will eventually experience visual loss. Despite
these limitations, individuals can be counselled based on
the two major identifiable risk factors in this disorder,
namely age and sex.1,2 Male carriers have about a 50%
lifetime risk of visual failure compared with only 10% for
female carriers, and the peak age of onset is in the second
and third decades of life. As a general health measure,
patients with mitochondrial disorders should be strongly
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advised not to smoke and to moderate their alcohol
intake. This is especially the case for unaffected LHON
carriers as smoking, and to a lesser extent excessive binge
drinking, has been linked with an increased risk of disease
conversion.42 It also seems sensible to avoid exposure to
other putative environmental triggers for visual loss in
LHON, in particular industrial toxins and drugs with
mitochondrial-toxic effects, for example ethambutol.1,2
DOA is an autosomal dominant Mendelian disorder,
and, although genetic counselling is straightforward,
providing accurate information about likely disease
severity is challenging for several reasons. It is not possible
to predict the rate of progression of visual loss, which can
be highly variable even within families harbouring the
same pathogenic OPA1 mutation.51 Furthermore, although
patients harbouring missense OPA1 mutations in the
GTPase domain of the protein have a statistically higher
risk of developing DOAþ phenotypes, not all of them will
do so, and the development of neurological features only
becomes manifest in mid- to late adulthood, introducing
another element of uncertainty.53 OPA1 mutation carriers
have a 50% chance of transmitting the pathogenic allele to
each of their children, and pregnant women can request
prenatal testing after having been appropriately
counselled. Prenatal diagnosis is possible by analysing
DNA extracted from fetal cells and the method used
will depend on the mother’s personal choice and her
gestational status, either amniocentesis (15–18 weeks)
or chorionic villus sampling (10–12 weeks).
Treatment options—LHON
Mitochondrial cocktails
There is currently only limited evidence to support the
use of any intervention in mitochondrial disorders.61 In a
recent systematic review of the literature, only 35 out of
1039 publications on treatments for mitochondrial
diseases included more than five patients, and most of
these studies suffered from significant methodological
weaknesses.62 Over the years, various combinations of
vitamins (B2, B3, B12, C, E, and folic acid) and other
compounds with putative mitochondrial antioxidant and
bioenergetics properties have been used to treat patients
with mitochondrial disease, including LHON, but none
with any convincing proof of efficacy.61–63 The list of
supplements that are frequently promoted on the
internet includes alpha-lipoic acid, carnitine, creatine,
and L-arginine.
Ubiquinone analogues
Ubiquinone is an essential carrier that ensures the
efficient transfer of electrons along the mitochondrial
respiratory chain. Pathogenic mtDNA mutations
associated with LHON destabilise complex I resulting in
a reduction in ATP synthesis and increased ROS levels.
An attractive strategy to restore the flow of electrons
along the mitochondrial respiratory chain is to bypass
the blockage occurring at the level of complex I by
enabling and maximising the direct shuttling of electrons
to complex III. Coenzyme Q10 (CoQ10) is a ubiquinone
analogue with a long history of use for patients with a
broad range of mitochondrial disorders.61–63 Although
there is a sound scientific basis based on the potential
antioxidant and bioenergetic properties of CoQ10, a
Cochrane review found no objective evidence of any
significant patient benefit in the limited number of small
studies that have been published.61 Putting these
methodological issues aside, the lack of efficacy of CoQ10
could be due to its lipophilic nature, this physical
property hindering its delivery to mitochondria
following oral administration of the drug. There is one
anecdotal report of an affected patient carrying the
m.11778G4A mutation who experienced marked visual
improvement after he was started on CoQ10 about 8
months following the first onset of symptoms.64 This
could simply have been a chance occurrence given that
spontaneous visual improvement has been noted in up to
25% of patients harbouring this mtDNA mutation.
Idebenone and EPI-743 are newer generation shorter-
chain analogues of ubiquinone that are reported to be
more potent compared with CoQ10, at least in vitro.28,65
The possible visual benefit of idebenone in LHON was
first reported in 1992 by Mashima and colleagues who
treated a 10-year-old boy harbouring the m.11778G4A
with a relatively low daily dose of 90 mg/day.66 The
obvious confounding factor in this case is the relatively
young age of the patient, as childhood-onset LHON
seems to be a distinct entity associated with a much more
benign clinical course and a higher rate of spontaneous
visual recovery.26 In a larger case series from the same
Japanese group, 14 patients with LHON were treated
with a combination of idebenone (180 mg/day), vitamin
B2, and vitamin C.
67 No significant difference in the
proportion of eyes showing visual recovery was
observed when this intervention group was
retrospectively compared with 14 untreated patients.
However, if it occurred, a faster rate of visual recovery
was reported in the treated eyes compared with the
untreated eyes. In contrast to these results, Barnils and
colleagues68 found no visual benefit with the use of the
same treatment cocktail in two visually affected
individuals carrying the m.11778G4A mutation.
To address the true potential of idebenone as a
treatment modality in LHON, a multicentre, double-
blind, randomised placebo-controlled trial was initiated.
RHODOS (Rescue of Hereditary Optic Disease
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Outpatient Study, ClinicalTrials.gov identifier:
NCT00747487) enrolled 85 patients with a confirmed
primary mtDNA mutation (m.3460G4A, m.11778G4A,
and m.14484T4C) and with disease duration of up to 5
years.28 The active arm received idebenone (900 mg/day),
and no adverse drug reactions occurred over a treatment
period of 24 weeks. This trial failed to show benefit for its
pre-specified primary end point (best recovery of visual
acuity at week 24), but all of the secondary end points
showed a positive trend towards visual improvement in
the idebenone-treated group. A post hoc analysis of the
trial data also indicated that patients with discordant
visual acuities (LogMAR40.2), and hence at highest risk
of further deterioration in the least affected eye, were
more likely to benefit from treatment with idebenone. In
the follow-up study (RHODOS-OFU), the beneficial
effect of 24 weeks of treatment with idebenone seemed to
persist following discontinuation of the active
medication at the end of the trial.69 In a large
retrospective Italian study involving 103 patients with
LHON, 44 patients with visual loss of 1 year’s duration
or less were treated with idebenone and followed for at
least 5 years.70 A greater proportion of patients receiving
idebenone recovered vision and the most consistent
prognostic factors associated with visual recovery were
the early initiation of treatment and a more prolonged
course of treatment.
A marketing authorisation application by Santhera
Pharmaceuticals Ltd (Liestal, Switzerland) to the
European Medicines Agency’s Committee for Medicinal
Products for Human Use (CHMP) has recently received
an unfavourable opinion and additional clinical evidence
for the efficacy of idebenone in LHON has been
requested by CHMP (http://www.santhera.com/index.
php?docid=212&vid=&lang=en&newsdate=201301
&newsid=1671337&newslang=en, accessed on 8
December 2013). The Newcastle Mitochondrial Research
Group is planning a second double-blind, randomised,
placebo-controlled trial that will investigate the benefit of
treatment with a higher dose of idebenone (2250 mg/day)
given for a total duration of 48 weeks instead of 24 weeks
as for RHODOS (Table 2). Further work is also needed to
determine the appropriate duration of treatment, once
initiated, and whether there is a place for the treatment of
asymptomatic carriers or patients with longstanding
visual loss. Although idebenone is currently not licensed
for clinical use, patients with LHON frequently opt to gain
access to it at their own expense from various internet
sources. EPI-743 has been used in an open-labelled study
of five patients with LHON who were treated within 90
days of disease conversion. Although the results need to
be confirmed in a properly designed clinical trial, four out
of five patients demonstrated arrest of disease progression
and variable extents of visual improvement.65
Brimonidine
Brimonidine is a topical a-2 agonist that is commonly
used to lower intraocular pressure in the management of
glaucoma.71 Some studies have suggested that
brimonidine can exert a synergistic RGC neuroprotective
effect by upregulating a number of antiapoptotic factors
and by blocking glutamate excitotoxicity induced by
mitochondrial oxidative stress.71 Topical brimonidine has
therefore been tested as a prophylactic agent for second-
eye involvement in an open-labelled study of nine
patients with unilateral acute visual loss secondary to
LHON.72 Brimonidine failed to prevent fellow eye
involvement, and there was no evidence of any visual
benefit following the onset of visual loss. Although this
study was negative, raised intraocular pressure has been
linked with an increased risk of visual loss in LHON and
an agent with putative neuroprotective properties such
as brimonidine could represent an ideal choice of
treatment for unaffected LHON carriers diagnosed with
glaucoma or ocular hypertension.73
Steroids and immunosuppressants
Patients with LHON are not infrequently treated with high-
dose steroids before a molecular diagnosis has been
secured to exclude the possibility of an inflammatory optic
neuropathy. Steroids do not prevent the involvement of the
fellow unaffected eye in LHON, and there has been no
reported benefit on disease progression and the final visual
outcome.63 In an in vitro experimental paradigm involving
the supplementation of the culture media with hydrogen
peroxide, LHON cybrids harbouring the m.11778G4A
mutation showed an increased sensitivity to oxidative
stress.74 This increased susceptibility to undergo apoptosis
was postulated to be secondary to a toxic rise in
intracellular calcium and the activation of the
mitochondrial transition pore (MTP). Pre-treatment with
cyclosporin A blunted the deleterious consequences of
hydrogen peroxide by blocking the MTP pore, indicating a
possible therapeutic pathway for LHON. The antiapoptotic
effect of cyclosporine A has also been demonstrated in
LHON cybrids harbouring the m.14484T4C and
m.14279G4A mutations.75 On the basis of these in vitro
data, a French study is currently underway recruiting
patients with unilateral visual loss from LHON for
treatment with cyclosporin A in an attempt to prevent
the involvement of the fellow eye (Dr Dominique Bonneau,
University of Angers, France, personal communication).
Hyperbaric oxygen therapy
There is highly anecdotal ‘internet’ evidence of patients
with LHON benefiting from hyperbaric oxygen therapy
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(HBOT) (http://hyperbariclink.blogspot.co.uk/2012/
06/in-news-hyperbaric-oxygen-therapy-for.html,
accessed on 8 December 2013). The purported rationale
for this treatment is to provide increased levels of oxygen
to RGCs during the acute phase of LHON with the aim
of improving mitochondrial biogenesis. HBOT is a
controversial treatment modality that has been applied
with limited success to other optic nerve disorders such
as radiation-induced optic neuropathy and anterior
ischaemic optic neuropathy.76 Given the rather slim
evidence base, the theoretical toxic effects of
supraphysiological levels of oxygen in LHON should be
considered in the context of a dysfunctional
mitochondrial respiratory chain that is already
producing increased ROS levels.
Near-infrared light therapy
Near-infrared light (NIR) therapy has been shown to
improve mitochondrial function and cellular survival
in various models of wound healing, neurodegeneration
and methanol-induced retinal toxicity.77 Although
these findings are not universally accepted and
the mechanisms are not fully understood, NIR
photobiomodulation is thought to increase ATP synthesis
by stimulating the activity of cytochrome c oxidase
(complex IV).77 The application of NIR therapy to
RGCs via a light-emitting diode has therefore been
proposed as a possible rescue strategy for LHON. A
study was initiated to investigate the visual benefit of
NIR therapy in affected LHON carriers, but it has been
terminated because of the inability to record reliable
pERG measurements, which was the planned primary
outcome measure, due to poor subject fixation
(http://clinicaltrials.gov/ct2/show/NCT01389817?term=
LHONþwhelan&rank=1, accessed on 8 December 2013).
Treatment options: DOA
Compared with LHON, the rate of RGC loss in DOA is
relatively slow and the detection of a clinically
meaningful benefit over the course of a 1- or 2-year
treatment trial is a major methodological consideration.
Long-term natural history studies are therefore urgently
needed to more precisely define the visual parameters
that are most sensitive at detecting a significant change in
optic nerve structure and function for insidiously
progressive optic nerve disorders like DOA (Table 2).
Idebenone has recently been evaluated in a limited case
series involving seven patients with DOA and confirmed
pathogenic OPA1 mutations.78 A variable daily dose of
idebenone was used (270–675 mg), and all the patients
were treated and reviewed for at least 1 year. No adverse
drug reactions were reported and some improvement
in visual function was reported for five of the seven
idebenone-treated patients. The results of this pilot
study remain preliminary and a randomised, placebo-
controlled trial with an adequate duration of follow-up
will be needed to prospectively evaluate the possible
benefit of using idebenone in DOA. Looking into the
future, an open-labelled study of EPI-743 for patients
with DOA is currently under preparation (Dr Valerio
Carelli, University of Bologna, Italy, personal
communication), and the potential benefit of near-
infrared light in rescuing RGC loss is also being tested in
a mouse model of DOA harbouring a splice site mutation
(c.1065þ 5g4a) within intron 10 of the Opa1 gene
(Professor Marcela Votruba, Cardiff University, UK).79
Future prospects and challenges
Drug screening and development
With idebenone and EPI-743, we are witnessing the first
tentative steps in our effort to try and modulate disease
progression for mitochondrial optic neuropathies.
Several research groups worldwide are actively pursuing
the identification of novel neuroprotective agents for
other, more prevalent, optic nerve disorders such as
glaucoma and anterior ischaemic optic neuropathy, the
results of which are likely to be highly relevant for
LHON and DOA.71,80 The technological revolution of the
past decade has also launched a new era of personalised
medicine with powerful complementary approaches that
combine the in vitro screening of small molecule libraries
with further in vivo validation using existing animal
models. Greater collaboration with the pharmaceutical
industry will be an important element of this major
translational push for rare genetic disorders. More than
ever, clinical academics will have an important role to
Table 2 Translational research initiatives for inherited optic neuropathies
The National Institute for Health Research (NIHR) is spearheading an ambitious translational research programme for rare genetic
diseases in the United Kingdom. Inherited optic neuropathies have been selected as one of the priority disease themes. As part of this
specific NIHR study, we will undertake deep phenotyping of patients with LHON and DOA to define the natural history of the visual
loss and to identify the most sensitive parameters for monitoring disease progression. Importantly, this study will provide useful
information on the visual outcome measures that are most likely to reveal a clinically meaningful treatment effect in future clinical
trials for pipeline neuroprotective agents. Please get in touch with us if you have eligible patients who could be enrolled into this
national initiative for translational research into inherited optic neuropathies.
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play in taking the lead and setting the broad directions
for the clinical evaluation and validation of new drugs
for inherited optic neuropathies. Some obvious
candidates are compounds that are thought to activate
mitochondrial biogenesis, for example oestrogen-like
molecules and acetyl-L-carnitine (ALCAR), which is
derived from the acetylation of L-carnitine within
mitochondria. ALCAR has the advantageous property
of crossing the blood–brain barrier, and this molecule
promotes OXPHOS by upregulating the transcript levels
of ‘master’ genes involved in mitochondrial biogenesis,
namely PGC-1a, PGC-1b, and TFAM.81,82 A study is
currently nearing completion looking at the effect of
ALCAR on neuronal conduction along the visual
pathways in patients with chronic LHON and disease
duration of more than 2 years (http://apps.who.int/
trialsearch/trial.aspx?trialid=EUCTR2009-016982-26-IT,
accessed on 8 December 2013).
Gene therapy
Gene replacement therapy for LHON is an attractive
strategy, given the easy anatomical accessibility of the
RGC layer for direct manipulation. However, the double-
membrane nature of mitochondria presents a formidable
series of technical challenges that need to be overcome.
First and foremost, a highly efficient vector is needed to
penetrate the relatively impermeable inner
mitochondrial membrane and to allow a sufficient
number of mitochondria to be transfected in order to
achieve the desired gene replacement effect. A possible
solution is to bypass the mitochondrial genome
altogether by using an elegant alternative approach that
relies on the nuclear allotopic expression of the gene of
interest.83 The relevant mtDNA gene can be efficiently
transfected into the nuclear compartment with an adeno-
associated virus (AAV) vector after it has been
reconfigured to fit the slightly different coding system
operating within the nuclear genome. This hybrid
nuclear-encoded protein has also been engineered with a
specific targeting sequence to facilitate its efficient import
into mitochondria, thereby compensating for the missing
or dysfunctional mitochondrial protein. The potential of
this gene therapy approach in rescuing the disease
phenotype was first demonstrated in m.11778G4A
LHON cybrids.84 The ability to rescue RGCs and
improve visual function was subsequently confirmed
in vivo by two independent research groups working on
LHON rodent models expressing mutated ND4
(m.11778G4A) complex I subunits.85,86 These
groundbreaking experiments are paving the way for
more advanced studies involving primates and
ultimately patients with LHON (http://www.gensight-
biologics.com/, accessed on 8 December 2013). However,
a note of caution is required here given the ongoing
debate as to whether the imported wild-type ND4
subunit actually integrates into the native complex
I to produce a stable functional unit within the
inner mitochondrial membrane.1
Proof-of-principle has also been demonstrated for two
other forms of gene therapy based on nuclear allotopic
expression. One strategy involves the transfection of the
nuclear genome with the neuroprotective SOD2 gene
packaged into an AAV vector.87 The overexpression of
the superoxide dismutase ROS scavenger in
m.11778G4A LHON cybrids suppressed apoptosis and
resulted in increased cell survival.87 The consolidation of
the cell’s antioxidant defences could therefore prove a
complementary approach to the replacement of the
mutated gene product in LHON. A radically different
strategy is based on the xenotopic expression of Ndi1, an
alternative NADH oxidase expressed in yeast
(Saccharomyces cerevisiae) mitochondria. Ndi1 is a
versatile enzyme that can bypass a malfunctioning
complex I to restore downstream electron transfer while
at the same time suppressing ROS overproduction.88
Successful rescue of optic nerve degeneration was
achieved using the yeast Ndi1 gene in a rat model of
LHON that was generated by the injection of rotenone-
loaded microspheres into the optic layer of the rat
superior colliculus.88
Despite the technical difficulties of directly
introducing genetic material into mitochondria, two
recent studies have suggested that this could be
achieved using two very different genetic engineering
approaches. In one study, whole circular mtDNA
molecules isolated from healthy human donors were
complexed with human recombinant TFAM, and this
genetic construct was able to gain direct entry into cells.
When applied to m.11778G4A LHON cybrids, this
novel strategy was able to restore cellular respiration
and ATP synthesis by promoting mitochondrial
biogenesis.89 In the other study, a mitochondrial
targeting sequence was attached to the capsid element
of an AAV vector carrying the replacement ND4 subunit
gene.90 This additional tag allowed the direct
introduction of the wild-type ND4 gene into the
mitochondrial compartment, leading to the successful
rescue of the pathological phenotype in both
m.11778G4A LHON cybrids and a mouse model
manifesting optic atrophy secondary to allotopic
expression of the human ND4 mutation.90 The
introduced ND4 gene construct is thought to remain
episomal, which should prevent the mutagenic
disruption of the endogenous genes contained within
the host mitochondrial genome.91 Although direct
mitochondrial gene delivery offers exciting therapeutic
potential, these potentially groundbreaking findings
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should be viewed as preliminary until they have been
independently replicated by other research groups.
Gene therapy for DOA is being contemplated for
affected patients harbouring truncating OPA1 mutations
that result in haploinsufficiency. The strategy being
developed involves the intravitreal injection of an AAV
vector to deliver the wild-type OPA1 gene to surviving
RGCs in a mouse model of DOA carrying the exon
27 (c.2708-2711delTTAG) mutation.92 Although
conceptually simpler than mitochondrial gene therapy,
further methodological refinements are needed to
achieve stable transfection in a sufficient proportion of
RGCs to result in a clinically meaningful effect (Dr Guy
Lenaers, University of Montpelier, France, personal
communication). It is important to emphasise that all the
gene therapy approaches being envisaged for LHON and
DOA are still at an early experimental stage of
development, and further evidence of their safety and
efficacy is needed before the initiation of human trials
can be contemplated.
Stem cells
The therapeutic potential of stem cells is being
investigated for a wide range of genetic eye disorders,
and patients with mitochondrial optic neuropathies will
frequently enquire with their clinicians whether they are
likely to benefit from this form of treatment.93 Various
poorly monitored ‘stem cell institutes’ worldwide are
promoting the use of non-validated experimental
protocols, and patients with LHON and DOA need to be
carefully advised before embarking on multiple
expensive courses of treatment with the possible
associated biological risks. In sharp contrast to this
unregulated parallel market, there are a number of well-
established research programmes that are rigorously
assessing the possible application of stem cell technology
for optic nerve disorders.93,94 Two main paradigms
are being explored, namely the generation and
transplantation of RGCs, or the use of specific stem cell
populations to generate trophic factors that promote
RGC survival.93,94 The technique for generating and
purifying mature RGCs from embryonic stem cells or
induced pluripotent stem cells is still in its infancy.
Another major complicating factor is how to integrate
these differentiated RGCs into the retina and then force
them to make the right topographical connection. At least
in the short term, it is more likely that human-derived
RGCs will provide the ideal tool for drug screening and
understanding the basic mechanisms regulating RGC
physiology in both health and disease states.71,95
A proportion of patients with LHON will experience
partial visual recovery, mostly within 1 year of being
affected, but sometimes several years after the onset
of the disease. It is therefore highly likely that a
subpopulation of RGCs that survived the initial massive
wave of apoptosis remain in a state of suspended
animation awaiting two possible fates: a final push
towards apoptosis or a gradual recovery of cellular
function. These surviving RGCs are being targeted by
oral neuroprotective agents, but mesenchymal stem cells
are also an interesting modality based on promising data
from experimental glaucoma and optic neuritis
studies.71,95 Autologous mesenchymal stem cells can be
isolated from bone marrow isolates, and they secrete
several diffusible neurotrophic factors that are thought to
promote neuronal survival in adverse metabolic and
excitotoxic environments. Rather encouragingly, the
injection of mesenchymal stem cells was well tolerated in
a small proof-of-concept study of 10 patients with
secondary progressive MS.96 Although not definitive,
there was a suggestion of structural, functional, and
physiological improvement in some visual end points
suggestive of a neuroprotective effect. If confirmed, a
similar strategy is entirely conceivable to halt or slow
down the irreversible loss of RGCs in LHON and DOA.
Prevention of germline transmission
In vitro fertilisation (IVF) techniques are currently being
developed to prevent female carriers of childbearing
age from transmitting pathogenic mtDNA mutations to
the next generation. Two different IVF options have
been proposed, namely pronuclear transfer and
metaphase II spindle transfer, to generate the so-called
‘three-parent embryos’ devoid of mutant mtDNA
molecules.97 The aim of both techniques is to transfer
the parental nuclear genetic material (devoid of the
mother’s mutant mtDNA molecules) into a donor
cytoplast containing a normal wild-type mtDNA
population. In the pronuclear technique, the male and
female pronuclei are transferred post fertilisation into a
mitochondrial donor zygote harbouring wild-type
mtDNA.98 The alternative approach involves the
transplantation of metaphase II spindles between
unfertilised oocytes followed by intracytoplasmic sperm
injection fertilisation.99 There seems to be no significant
carryover of mutant mtDNA with both IVF approaches,
and further work is currently underway in higher
primates.98,100 Preventing the germline transmission
of pathogenic mtDNA mutations is an exciting
development, but a stringent series of safety tests will
first need to be fulfilled. A significant proportion of
manipulated zygotes showed abnormal development
and other iatrogenic genetic consequences must be
considered, including an increased risk of aneuploidy
and epigenetic abnormalities.97 The manipulation of
human embryos also entails a number of important
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legal, religious, and ethical ramifications that will need
to be addressed. The United Kingdom has been at the
forefront of this important debate and an expert panel
was recently convened by the Human Fertilisation
and Embryology Authority (HFEA) to review the
fertilisation methods that could be used to prevent
mitochondrial disease. This public consultation
indicated positive support for mitochondria
replacement to take place, but subject to strict
safeguards and careful regulation being adhered to
(https://www.gov.uk/government/news/innovative-
genetic-treatment-to-prevent-mitochondrial-disease,
accessed on 8 December 2013).
Conclusion
Translational research for mitochondrial optic
neuropathies is entering an exciting accelerated phase
providing renewed hopes to patients and their families
that the inexorable visual loss associated with this group
of disorders can at least be halted. We still need a better
understanding of the pathological mechanisms
underpinning the preferential vulnerability of RGCs in
LHON and DOA, but these more basic studies are now
proceeding in parallel with major national and
transnational initiatives aimed at drug development and
early phase clinical trials. The establishment of patient
cohorts will provide a strong base to launch properly
designed randomised, placebo-controlled trials and the
prospective collection of long-term natural history data
will be essential to identify the best outcome measures to
detect a treatment benefit. The challenges of identifying
and validating treatments for relatively rare inherited
optic nerve disorders remain daunting, but 25 years after
the birth of mitochondrial genetic medicine, tractable
solutions are finally emerging.
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